Generica, a Slovakian private dietary supplements company ,active in Eastern Europe, intends to launch in the beginning of 2008, its LIPIDIA product, featuring Enzymotec’s CardiaBeat™ . CardiaBeat™ is an innovative matrix which delivers conjugated plant sterols to omega 3 fatty acids, having a greater impact on cardiovascular disease (CVD) risk reduction. Recently, it has won the 2007 NutrAward price and gained GRAS , NDI (US) and novel food approval in the EU.
This launch follows recent collaborations with different companies in Europe ,India, Australia, South Korea and the USA.
"The regulatory approval we have received in 2007 has enabled us to present this product in the European market and to successfully establish agreements in several countries" says Ms. Michal Haim-Bravman, Enzymotec’s marketing manager.
Generica LTD is a Slovakian producer of nutraceuticals and cosmeceuticals active in Eastern Europe countries. Its product portfolio includes tablets, soft gelatin capsules, ointments, gels, sprays, foams and powder sprays. Generica distributes its own assortment (64 preparates) via wholesalers to pharmacies exclusively. Generica also manufactures for other companies by contract manufacturing.
Enzymotec is a developer and manufacturer of innovative, lipid-based biofunctional ingredients for dietary supplements, functional foods, clinical nutrition and advanced infant nutrition. Key products are: SharpPS™ line of products- phosphatidylserine based ingredients for cognitive improvement, InFat™ - structured fat for infant formulas , Krill Oil+ ™ and CardiaBeat™
Ms. Michal Haim-Bravman